IMGN News and Press, ImmunoGen Inc. From 09/17/20

Triplet Combination Demonstrates Encouraging Anti-Tumor Activity and Tolerability in Recurrent Platinum-Sensitive Ovarian Cancer ImmunoGen, Inc. , (Nasdaq: IMGN) a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced final data ...

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will present at the upcoming H.C. Wainwright Virtual Glo...

The stock market is filled with individuals who know the price of everything, but the value of nothing. - Phillip Fisher In the cancer research world, the space of antibody-drug conjugates has performed an interesting resurrection in recent years. Yes, they’ve been approved sinc...

ImmunoGen ( IMGN ) is a late clinical stage pharmaceutical company with a potential cancer therapy. It was once a relatively high-flyer, with a stock price about 5 times today's, back in July of 2013. That was based largely on early trial data from the drug Mirvetuximab soravtansine, or mirv. ...

Image source: The Motley Fool. Immunogen Inc   (NASDAQ: IMGN) Q2 2020 Earnings Call Jul 31, 2020 , 8:00 a.m. ET Operator Continue reading

ImmunoGen, Inc. (IMGN) Q2 2020 Results Earnings Conference Call July 31, 2020, 08:00 AM ET Company Participants Courtney O'Konek - Senior Director, Corporate Communications and Investor Relations Mark Enyedy - President and Chief Executive Officer Susan Altschuller - Senior Vice ...

ImmunoGen ( IMGN -6.8% ) Q2 results : More news on: ImmunoGen, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...

Encouraging Data from FORWARD II Study of Mirvetuximab in Combination with Avastin ® in Recurrent Ovarian Cancer, Regardless of Platinum Status, Presented at ASCO Preclinical Data on Next Generation Anti-FRα ADC, IMGN151, Demonstrating Enhanced Anti-Tumor Activity, Present...

ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming 40 th Annual Canaccord Genuity Virtual Growth Co...

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, PhD has been appointed Senior Vice President and Chief Financial Officer. “Susan is an outstanding addition to o...